Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

6533b85bfe1ef96bd12babb8

RESEARCH PRODUCT

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

Uwe Mittler Heiko Goette Niels Soerensen Christian Urban Frank Deinlein Paul G. Schlegel Rolf D. Kortmann Monika Warmuth-metz Martin Benesch Stefan Rutkowski Stefan Rutkowski Torsten Pietsch Bernward Hinkes Katja Von Hoff Isabella Zwiener Joachim Kuehl Nicolas U. Gerber

subject

Male Cancer Research Vincristine Pediatrics medicine.medical_specialty Neoplasm Residual Adolescent medicine.medical_treatment Antineoplastic Agents Drug Administration Schedule law.invention Maintenance therapy Randomized controlled trial law medicine Humans Cerebellar Neoplasms Child Survival rate Neoplasm Staging Proportional Hazards Models Medulloblastoma Chemotherapy business.industry Proportional hazards model Neoplasms Second Primary medicine.disease Combined Modality Therapy Survival Rate Clinical trial Treatment Outcome Oncology Vincristine Child Preschool Female Neoplasm Recurrence Local business Follow-Up Studies Medulloblastoma medicine.drug

description

PURPOSE: To analyse long-term outcome and clinical prognostic factors in medulloblastoma. METHODS: We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years). RESULTS: In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independent adverse risk factors. Twelve percent of all relapses (13 of 107) occurred after more than five years, and 12 patients had secondary neoplasms. CONCLUSIONS: After maintenance therapy, long-term survival was excellent in fully assessable patients with localised medulloblastoma, and favourable for M1 patients. Patients should be followed longer for late relapses and secondary tumours.

year	journal	country	edition	language
2009-05-01	European Journal of Cancer

https://doi.org/10.1016/j.ejca.2009.01.015